Monday, October 17, 2016

Opana ER


See also: Generic Opana


Opana ER is a brand name of oxymorphone, approved by the FDA in the following formulation(s):


OPANA ER (oxymorphone hydrochloride - tablet, extended release; oral)



  • Manufacturer: ENDO PHARMS

    Approval date: June 22, 2006

    Strength(s): 10MG [AB], 20MG [AB], 40MG [RLD][AB], 5MG [AB]


  • Manufacturer: ENDO PHARMS

    Approval date: February 29, 2008

    Strength(s): 30MG [AB]


  • Manufacturer: ENDO PHARMS

    Approval date: December 9, 2011

    Strength(s): 10MG, 15MG, 20MG, 30MG, 40MG, 5MG, 7.5MG

Has a generic version of Opana ER been approved?


A generic version of Opana ER has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Opana ER and have been approved by the FDA:


oxymorphone hydrochloride tablet, extended release; oral



  • Manufacturer: IMPAX LABS

    Approval date: June 14, 2010

    Strength(s): 10MG [AB], 20MG [AB], 40MG [AB], 5MG [AB]


  • Manufacturer: IMPAX LABS

    Approval date: July 22, 2010

    Strength(s): 30MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Opana ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Controlled release formulation (albuterol)
    Patent 5,662,933
    Issued: September 2, 1997
    Inventor(s): Baichwal; Anand & McCall; Troy W.
    Assignee(s): Edward Mendell Co., Inc.
    A sustained release pharmaceutical formulation and methods of making and using the same are provided. The sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional hydrophobic material and/or hydrophobic coating, and a medicament for sustained oral administration.
    Patent expiration dates:

    • September 9, 2013
      ✓ 
      Drug product




  • Controlled release formulation (albuterol)
    Patent 5,958,456
    Issued: September 28, 1999
    Inventor(s): Baichwal; Anand & McCall; Troy W.
    Assignee(s): Edward Mendell Co., Inc.
    A sustained release pharmaceutical formulation and methods of making and using the same are provided. The sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional hydrophobic material and/or hydrophobic coating, and a medicament for sustained oral administration.
    Patent expiration dates:

    • September 9, 2013
      ✓ 
      Drug product




  • Sustained release formulations of oxymorphone
    Patent 7,276,250
    Issued: October 2, 2007
    Inventor(s): Baichwal; Anand R. & Kao; Huai-Hung & McCall; Troy W.
    Assignee(s): Penwest Pharmaceuticals Company
    Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Patent expiration dates:

    • February 4, 2023
      ✓ 
      Patent use: RELIEF OF MODERATE TO SEVERE PAIN
      ✓ 
      Drug product




  • Abuse-proofed dosage form
    Patent 8,075,872
    Issued: December 13, 2011
    Inventor(s): Arkenau-Maric; Elisabeth & Bartholomäus; Johannes & Kugelmann; Heinrich
    Assignee(s): Gruenenthal GmbH
    The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.
    Patent expiration dates:

    • November 20, 2023
      ✓ 
      Drug product



See also...

  • Opana ER Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Opana ER Consumer Information (Cerner Multum)
  • Opana ER Advanced Consumer Information (Micromedex)
  • Oxymorphone Consumer Information (Wolters Kluwer)
  • Oxymorphone Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Oxymorphone Suppositories Consumer Information (Wolters Kluwer)
  • Oxymorphone Tablets Consumer Information (Wolters Kluwer)
  • Oxymorphone Consumer Information (Cerner Multum)
  • Oxymorphone Advanced Consumer Information (Micromedex)
  • Oxymorphone Injection Advanced Consumer Information (Micromedex)
  • Oxymorphone Hydrochloride AHFS DI Monographs (ASHP)

No comments:

Post a Comment